Purple Biotech Stock Shares Owned By Institutions
| PPBT Stock | USD 0.51 0.01 1.26% |
Purple Biotech fundamentals help investors to digest information that contributes to Purple Biotech's financial success or failures. It also enables traders to predict the movement of Purple Stock. The fundamental analysis module provides a way to measure Purple Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Purple Biotech stock.
Purple | Shares Owned By Institutions |
Purple Biotech Company Shares Owned By Institutions Analysis
Purple Biotech's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Purple Biotech Shares Owned By Institutions | 8.28 % |
Most of Purple Biotech's fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Purple Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Purple Shares Owned By Institutions Driver Correlations
Understanding the fundamental principles of building solid financial models for Purple Biotech is extremely important. It helps to project a fair market value of Purple Stock properly, considering its historical fundamentals such as Shares Owned By Institutions. Since Purple Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Purple Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Purple Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 8.28099999999999% of Purple Biotech are shares owned by institutions. This is 81.45% lower than that of the Biotechnology sector and 82.57% lower than that of the Health Care industry. The shares owned by institutions for all United States stocks is 78.88% higher than that of the company.
Purple Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Purple Biotech's direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Purple Biotech could also be used in its relative valuation, which is a method of valuing Purple Biotech by comparing valuation metrics of similar companies.Purple Biotech is currently under evaluation in shares owned by institutions category among related companies.
Purple Fundamentals
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | 120.48 M | ||||
| Shares Outstanding | 26.11 M | ||||
| Shares Owned By Insiders | 3.80 % | ||||
| Shares Owned By Institutions | 8.28 % | ||||
| Number Of Shares Shorted | 297.21 K | ||||
| Price To Book | 0.47 X | ||||
| Price To Sales | 58.08 X | ||||
| Gross Profit | (120 K) | ||||
| EBITDA | (22.07 M) | ||||
| Net Income | (19.88 M) | ||||
| Cash And Equivalents | 36.02 M | ||||
| Cash Per Share | 2.00 X | ||||
| Total Debt | 351 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 6.94 X | ||||
| Book Value Per Share | 0.14 X | ||||
| Cash Flow From Operations | (19.23 M) | ||||
| Short Ratio | 1.30 X | ||||
| Earnings Per Share | (0.90) X | ||||
| Target Price | 9.67 | ||||
| Number Of Employees | 20 | ||||
| Beta | 0.57 | ||||
| Market Capitalization | 13.59 M | ||||
| Total Asset | 44.3 M | ||||
| Retained Earnings | (137.45 M) | ||||
| Working Capital | 8.61 M | ||||
| Net Asset | 44.3 M |
About Purple Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Purple Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Purple Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Purple Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Purple Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Purple Biotech Piotroski F Score and Purple Biotech Altman Z Score analysis. For more information on how to buy Purple Stock please use our How to Invest in Purple Biotech guide.Note that the Purple Biotech information on this page should be used as a complementary analysis to other Purple Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for Purple Stock analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
Is Purple Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Purple Biotech. If investors know Purple will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Purple Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Return On Assets (0.28) | Return On Equity (0.49) |
The market value of Purple Biotech is measured differently than its book value, which is the value of Purple that is recorded on the company's balance sheet. Investors also form their own opinion of Purple Biotech's value that differs from its market value or its book value, called intrinsic value, which is Purple Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Purple Biotech's market value can be influenced by many factors that don't directly affect Purple Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Purple Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Purple Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Purple Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.